The NPPA took a decision of revision of price under Para 19 of Drugs (Prices Control) Order, 2013 based on the decision of 89th Authority meeting dated 28.06.2021. In this important decision, NPPA revised upward the prices of Carbamazepine, Ranitidine, and Ibuprofen formulations in different strengths. Get the consolidated list of DPCO prices of Ranitidine tablets and Carbamazepine and Ibuprofen tablets.
Latest DPCO price of Ranitidine 150mg and 300 mg tablets
The price of Ranitidine tablets 150 mg and 300 mg revised from Rs. 0.73 to Rs. 1.10 for 150 mg and 1.62 to Rs. 2.43 for 300 mg tablet.
Latest DPCO price of Carbamazepine 200mg and 400 mg tablets
The price of Carbamazepine CR tablets 200 mg and 400 mg revised from Rs. 1.56 to Rs. 2.34 per tablet for 200 mg and 3.07 to Rs. 4.61 for 400 mg tablet.
Latest DPCO price of Ibuprofen 200mg and 400 mg tablets
Similarly, the price of Ibuprofen tablets 200 mg and 400 mg was revised from Rs. 0.39 to Rs. 0.59 per tablet for 200 mg and 0.69 to Rs. 1.04 for 400 mg tablet
According to Order No. S.O. 2654(E) – Whereas the National Pharmaceutical Pricing Authority (NPPA) was established vide the Resolution of the Government of India in the Ministry of Chemicals and Fertilizers No. 33/7/97-PI. dated 29th August 1997, inter-alia, to fix prices and notify the changes therein, if any, of bulk drugs and formulations, monitor the prices of non-scheduled drugs and formulations, and oversee the implementation of the provisions of the Drugs (Price Control) Order (DPCO)
Also Read: Pharma top 10 companies in India
DPCO prices of Ranitidine tablets and 2 more.
|Name of the Scheduled Formulation||Dosage form & Strength||Unit||Ceiling Price (Rs.)||Existing S.O. No.||Date|
|1||Carbamazepine||Oral Liquid 100 mg/5ml||1 ml||0.29||1330(E) Sl. No. 139||25.03.2021|
|2||Carbamazepine||CR Tablet 200 mg||1 tablet||2.34||1330(E) Sl. No. 140||25.03.2021|
|3||Carbamazepine||CR Tablet 400 mg||1 tablet||4.61||1330(E) Sl. No. 141||25.03.2021|
|4||Carbamazepine||Tablet 100 mg||1 tablet||1.02||1330(E) Sl. No. 142||25.03.2021|
|5||Ranitidine||Oral Liquid 75 mg/5ml||1 ml||1.08||1330(E) Sl. No. 722||25.03.2021|
|6||Ranitidine||Tablet 150 mg||1 tablet||1.1||1330(E) Sl. No. 723||25.03.2021|
|7||Ranitidine||Injection 25mg/ml||1 ml||2.43||1330(E) Sl. No. 724||25.03.2021|
|8||Ibuprofen||Tablet 200 mg||1 tablet||0.59||1330(E) Sl. No. 431||25.03.2021|
|9||Ibuprofen||Tablet 400 mg||1 tablet||1.04||1330(E) Sl. No. 432||25.03.2021|
Note: Read important note and terms and conditions apllied on the table prices.
(a) All manufacturers of scheduled formulation, selling the branded or generic or both the versions of
scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as
applicable) so fixed and notified by the Government, shall revise the prices of all such formulations
downward not exceeding the ceiling price specified in column (5) in the above table plus Goods
and Services Tax as applicable, if any.
(b) The provisions of para 13(2) of DPCO 2013 would not be applicable on the ceiling price specified
in column (5) in respect of the formulations with dosage & strength mentioned in columns (2) and
(c) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is
payable to the Government on the ceiling price mentioned in column (5) of the above-said table.
(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned
manufacturer in accordance with the ceiling price specified in column (5) of the above table as per
provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from the date of Notification as per paragraph 24 of the DPCO, 2013
to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display a price list and the
supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the
premises where he carries on business in a manner so as to be easily accessible to any person
wishing to consult the same.
(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as
specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such
the existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I
as specified under Schedule-II of the DPCO, 2013.
(g) The manufacturers of above said scheduled formulations shall furnish a quarterly return to the
NPPA, in respect of production/import and sale of scheduled formulations in Form-III of
Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue
production of above said scheduled formulation shall furnish information to the NPPA, in respect
of discontinuation of production and/or import of scheduled formulation in Form-IV of ScheduleII of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be
liable to deposit the overcharged amount along with interest thereon under the provisions of the
Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
(i) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above
the table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the
above said date of notification, stand(s) superseded.
Also Read: Latest DPCO list 2021
For Third, Party Manufacturing feel free to share your queries on Whatsapp.
The author has 20 years of experience in the Pharmaceutical Manufacturing Companies. Have exposure to all audit documents for WHO-GMP, PIC/S, USFDA, Export documents, US-FDA documents, Validation of Pharma machinery, and Quality Control Instruments. Expert in Pharma Plant Setup and sale and acquisition of running pharma company.